<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03167918</url>
  </required_header>
  <id_info>
    <org_study_id>20140721</org_study_id>
    <nct_id>NCT03167918</nct_id>
  </id_info>
  <brief_title>Lung Function in Patients With Early Type 2 Diabetes Mellitus</brief_title>
  <official_title>Liaoning University of Traditional Chinese Medicine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Liaoning University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Liaoning University of Traditional Chinese Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the protective effect of calcium dobesilate, Xuefuzhuyu Decoction, calcium
      dobesilate combined with Xuefuzhuyu Decoction on the early lung function of type 2 diabetes
      mellitus
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Test group and treatment: the patients with type 2 diabetes mellitus were randomly divided
      into calcium dobesilate group, Xuefuzhuyu Decoction group and combination group. All
      participants were given hypoglycemic, metformin (1000 mg, bid, PO), Mecobalamin Tablets,
      nerve nutrition (0.5 mg bid, PO): treatment. Calcium dobesilate group were given
      hypoglycemic, metformin (500 mg tid, PO), to improve the circular Calcium Dobesilate Capsules
      (0.5 g bid, PO), Mecobalamin Tablets, nerve nutrition (0.5 mg bid, PO): treatment. Xuefuzhuyu
      Decoction group was given hypoglycemic, metformin (500 mg tid, PO), to improve the circular
      Xuefuzhuyu Decoction (100 ml bid, PO), Mecobalamin Tablets, nerve nutrition (0.5 mg bid, PO):
      treatment. The combined treatment group was given metformin hypoglycemic (500 mg tid, PO),
      Calcium Dobesilate Capsules, improve circulation (0.5 g bid, PO) + Xuefuzhuyu Decoction (100
      ml, bid, PO), Mecobalamin Tablets, nerve nutrition (0.5 mg bid, PO). Before treatment, three
      groups of patients with blood glucose, oxidation related indicators, retrobulbar hemodynamics
      and pulmonary function were recorded.

      Detection: continuous treatment were observed before and after treatment of the three groups
      of patients after 24 weeks of fasting blood glucose (FBG), 2 hour postprandial blood glucose
      (2hPBG), body mass index (BMI), peripheral blood glycated hemoglobin (HbA1c) and related
      indexes of oxidation, superoxide dismutase (SOD), glutathione peroxidase, Gu Guang (GSH-Px),
      reactive oxygen species (ROS) activity, malondialdehyde (MDA) concentration and pulmonary
      function, vital capacity (VC%), forced vital capacity (FVC%), one second forced expiratory
      flow (FEV1%), peak expiratory flow (PEF%), maximal voluntary ventilation (MVV%), total lung
      capacity (TCL%) and a second rate (FEV1/FVC%), diffusion capacity of the lung for carbon
      monoxide (DLCO%), lung volume diffusion capacity of carbon monoxide (DLCO/VA%) changes of the
      central retinal artery (CRA) and posterior ciliary artery (PCA), eye movement The changes of
      blood flow velocity and resistance index (RI) of the pulse (AO) systolic and diastolic blood
      flow were recorded.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 21, 2014</start_date>
  <completion_date type="Actual">May 1, 2017</completion_date>
  <primary_completion_date type="Actual">April 1, 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in pulmonary function parameters</measure>
    <time_frame>26 weeks</time_frame>
    <description>The primary endpoints were the between-group differences in the changes in pulmonary function parameters between pretherapy and posttreatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in glycosylated hemoglobinA1c, fasting plasma glucose, 2-hour postprandial blood glucose,</measure>
    <time_frame>26 weeks</time_frame>
    <description>The secondary endpoints were changes from baseline to week 26 in glycosylated hemoglobinA1c, fasting plasma glucose, 2-hour postprandial blood glucose,. The tertiary endpoints were the changes from baseline to week 26 in blood-fat</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in blood-fat in Systolic blood pressure,Diastolic blood pressure, and blood-fat</measure>
    <time_frame>26 weeks</time_frame>
    <description>The quartus endpoints were the changes from baseline to week 26 in Systolic blood pressure,Diastolic blood pressure, and blood-fat</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in retrobulbar hemodynamics (RI)</measure>
    <time_frame>26 weeks</time_frame>
    <description>The fifth endpoints were the changes from baseline to week 26 in retrobulbar hemodynamics (RI) in the bilateral central retinal artery,posterior ciliary artery, endarteria ophthalmica.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Pulmonary Function</condition>
  <arm_group>
    <arm_group_label>Calcium dobesilate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>gave each patient metformin (1000 mg, bid, PO), Mecobalamin Tablets, (0.5 mg bid, PO) and Calcium dobesilate 0.5 g bid, PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xuefuzhuyu Decoction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>gave each patient metformin (1000 mg, bid, PO), Mecobalamin Tablets, (0.5 mg bid, PO) and Xuefuzhuyu Decoction 100 ml bid，po</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xuefuzhuyu Decoction &amp;Calcium dobesilate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>gave each patient metformin (1000 mg, bid, PO), Mecobalamin Tablets, (0.5 mg bid, PO) and Calcium dobesilate (0.5 g bid, PO)&amp; Xuefuzhuyu Decoction（100 ml bid，po)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium Dobesilate</intervention_name>
    <description>gave each patient 0.5 g bid，</description>
    <arm_group_label>Calcium dobesilate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xuefuzhuyu Decoction</intervention_name>
    <description>gave each patient100 ml bid，po</description>
    <arm_group_label>Xuefuzhuyu Decoction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xuefuzhuyu Decoction &amp; Calcium dobesilate</intervention_name>
    <description>gave each patient Calcium dobesilate 0.5 g bid，po and Xuefuzhuyu Decoction 100 ml bid，po</description>
    <arm_group_label>Xuefuzhuyu Decoction &amp;Calcium dobesilate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>gave each patient 1000 mg, bid, PO</description>
    <arm_group_label>Calcium dobesilate</arm_group_label>
    <arm_group_label>Xuefuzhuyu Decoction</arm_group_label>
    <arm_group_label>Xuefuzhuyu Decoction &amp;Calcium dobesilate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mecobalamin Tablets</intervention_name>
    <description>gave each patient 0.5 mg bid, PO</description>
    <arm_group_label>Calcium dobesilate</arm_group_label>
    <arm_group_label>Xuefuzhuyu Decoction</arm_group_label>
    <arm_group_label>Xuefuzhuyu Decoction &amp;Calcium dobesilate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. patients who were diagnosed with type 2 diabetes mellitus according to the guidelines
             of the American Diabetes Association ;

          2. had no history of smoking, pulmonary disease, cold, or pulmonary infection within a
             two-week period;

          3. were not diagnosed with hepatopathy, nephropathy, hyperuricemia, or gastrointestinal
             disease;

          4. were likely to have good compliance and were able to visit our hospital for periodic
             assessments.

        Exclusion Criteria:

          1. , type 1 diabetes, pregnant women;

          2. there are important organ dysfunction;

          3. the need to control blood glucose after insulin injection (poor drug control);

          4. the life of patients with irregular or serious addiction (alcoholism),

          5. poor compliance and compliance;

          6. the experiment of drug intolerance (severe allergic reaction 6);

          7. hypertension and hyperuricemia;

          8. and nearly two weeks colds, pneumonia and other respiratory diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiao-lin Jiang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liaoning University of Traditional Chinese Medicine</affiliation>
  </overall_official>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2017</study_first_submitted>
  <study_first_submitted_qc>May 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2017</study_first_posted>
  <last_update_submitted>May 24, 2017</last_update_submitted>
  <last_update_submitted_qc>May 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Liaoning University of Traditional Chinese Medicine</investigator_affiliation>
    <investigator_full_name>Xiaolin Jiang</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>calcium dobesilate</keyword>
  <keyword>Xuefuzhuyu Decoction</keyword>
  <keyword>pulmonary function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Calcium Dobesilate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

